SciNeuro
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Maryland, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
9808 Medical Center Dr Ste 470, Rockvill...Website
www.scineuro.comRevenue
$7.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
2
1
1
About SciNeuro
SciNeuro Pharmaceuticals is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases. Since its founding in 2020, SciNeuro has built a portfolio of pipeline programs staged from discovery to clinical development by addressing three key disease-driving mechanisms of neurodegeneration neurovascular inflammation, proteinopathy, and immune response. The company aims to develop disease-modifying treatment options for Alzheimer's disease, Parkinson's disease, and other devastating CNS diseases.Explore more
SciNeuro Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SciNeuro your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if SciNeuro is spiking on competitors!
Product Launch: Get notified when SciNeuro launches new products
Earning: See what the market has to say on SciNeuro recently announced quarterly report
Funding: Get notified immidiatlly once SciNeuro has new funding data
Congratulate Masked Content for being promoted to Masked Content at SciNeuro
Website visits: Recent activity has been detected on your website
Click to see if SciNeuro had a recent Job posting/layoffs
Check if SciNeuro has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
SciNeuro, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined SciNeuro as Masked Content
Find more new buyers
Compare Similar Companies to SciNeuro
Compare insights from companies similar to SciNeuro, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
SciNeuro is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
SciNeuro is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about SciNeuro.
SciNeuro financials insights
Gather financial insights about SciNeuro, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Private Equity
$53M
SciNeuro Tech Stack
A closer look at the technologies used by SciNeuro
Most Recent Scoops
Funding
Funding
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
New Hire
Executive Move
SciNeuro News & Media
SciNeuro and Novartis sign global licensing deal for Alzheimer’s antibody
Under the deal, SciNeuro will receive $165m upfront and could earn up to $1.5bn in milestones.SciNeuro and Novartis Enter into a Licensing and Collaboration Agreement for Next Generation Therapeutics to Treat Alzheimer's Disease
ROCKVILLE, Md. , Jan. 12, 2026 /PRNewswire/ -- SciNeuro grants Novartis an exclusive worldwide license to develop SciNeuro's novel antibody program that leverages a proprietary shuttle technology to enhance brain delivery of therapeutic agents to treat Alzheimer's Disease SciNeuro and...An Arch-backed biotech raises $53M to fight neurodegeneration | BioPharma Dive
SciNeuro Pharmaceuticals represents the latest in a string of Arch investments directed at the nervous system, a notoriously challenging area of drug development.SciNeuro Pharmaceuticals Lands $53M
ROCKVILLE, MD, SciNeuro Pharmaceuticals today announced the completion of a total of $53 million in equity financing.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding SciNeuro
Sign Up For FreeTo access detailed company insights
SciNeuro Pharmaceuticals is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases. Since its founding in 2020, SciNeuro has built a portfolio of pipeline programs staged from discovery to clinical development by addressing three key disease-driving mechanisms of neurodegeneration neurov... Read More
